Mcl-1 and anticancer vaccination: identification of an HLA-A2-restricted epitope

被引：4

作者：

Andersen, R. S. ^{[1
]}

Wenandy, L. ^{[1
]}

Sorensen, R. B. ^{[1
]}

Straten, P. thor ^{[1
]}

Andersen, M. H. ^{[1
]}

机构：

[1] Herlev Univ Hosp, Dept Hematol, CCIT, DK-2730 Herlev, Denmark

来源：

LEUKEMIA | 2008年 / 22卷 / 03期

关键词：

D O I：

10.1038/sj.leu.2404937

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

引用

收藏

页码：668 / 669

页数：2

相关论文

共 11 条

[1]

Identification of an HLA-A1 restricted CTL epitope from Mcl-1 [J].

Andersen, MH ;

Kvistborg, P ;

Becker, JC ;

Straten, PT .

LEUKEMIA, 2005, 19 (06) :1084-1085

[2]

Regulators of apoptosis: Suitable targets for immune therapy of cancer [J].

Andersen, MH ;

Becker, JC ;

Straten, PT .

NATURE REVIEWS DRUG DISCOVERY, 2005, 4 (05) :399-409

[3]

The antiapoptotic member of the Bcl-2 family Mcl-1 is a CTL target in cancer patients [J].

Andersen, MH ;

Becker, JC ;

Straten, PT .

LEUKEMIA, 2005, 19 (03) :484-485

[4]

PRODUCTION OF MONOCLONAL ANTIBODIES TO GROUP-A ERYTHROCYTES, HLA AND OTHER HUMAN CELL-SURFACE ANTIGENS - NEW TOOLS FOR GENETIC-ANALYSIS [J].

BARNSTABLE, CJ ;

BODMER, WF ;

BROWN, G ;

GALFRE, G ;

MILSTEIN, C ;

WILLIAMS, AF ;

ZIEGLER, A .

CELL, 1978, 14 (01) :9-20

[5]

Combination of chemotherapy and immunotherapy for cancer: a paradigm revisited [J].

Gabrilovich, Dmitry I. .

LANCET ONCOLOGY, 2007, 8 (01) :2-3

[6]

An integrative approach to CTL epitope prediction: A combined algorithm integrating MHC class I binding, TAP transport efficiency, and proteasomal cleavage predictions [J].

Larsen, MV ;

Lundegaard, C ;

Lamberth, K ;

Buus, S ;

Brunak, S ;

Lund, O ;

Nielsen, M .

EUROPEAN JOURNAL OF IMMUNOLOGY, 2005, 35 (08) :2295-2303

[7]

Complete remission in a patient with recurrent acute myeloid leukemia induced by vaccination with WT1 peptide in the absence of hematological or renal toxicity [J].

Mailänder, V ;

Scheibenbogen, C ;

Thiel, E ;

Letsch, A ;

Blau, IW ;

Keilholz, U .

LEUKEMIA, 2004, 18 (01) :165-166

[8]

Part II: Vaccines for haematological malignant disorders [J].

Mocellin, S ;

Semenzato, G ;

Mandruzzato, S ;

Rossi, CR .

LANCET ONCOLOGY, 2004, 5 (12) :727-737

[9]

Identification of known and novel immunogenic T-cell epitopes from tumor antigens recognized by peripheral blood T cells from patients responding to IL-2-based treatment [J].

Scheibenbogen, C ;

Sun, YS ;

Keilholz, U ;

Song, MX ;

Stevanovic, S ;

Asemissen, AM ;

Nagorsen, D ;

Thiel, E ;

Rammensee, HG ;

Schadendorf, D .

INTERNATIONAL JOURNAL OF CANCER, 2002, 98 (03) :409-414

[10]

Recent advances in the development of anticancer agents targeting cell death inhibitors in the Bcl-2 protein family [J].

Shangary, S ;

Johnson, DE .

LEUKEMIA, 2003, 17 (08) :1470-1481